Momenta Pharmaceuticals Inc (MNTA)

24.59 -2.61  -9.60% NASDAQ Apr 1, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
05/01/2020 08:00 EDT Misc Momenta Pharmaceuticals Inc First Quarter Earnings Conference Call in 2020
05/01/2020 Earnings Momenta Pharmaceuticals Inc First Quarter Earnings in 2020 Release
02/27/2020 Misc Momenta Pharmaceuticals Inc Annual Report for 2019
02/26/2020 08:30 EST Misc Momenta Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2019
02/26/2020 Earnings Momenta Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release
10/31/2019 08:30 EDT Misc Momenta Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019
10/31/2019 Earnings Momenta Pharmaceuticals Inc Third Quarter Earnings for 2019 Release
08/02/2019 08:30 EDT Misc Momenta Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019
08/02/2019 Earnings Momenta Pharmaceuticals Inc Second Quarter Earnings in 2019 Release
06/19/2019 10:30 EST Misc Momenta Pharmaceuticals Inc Annual General Meeting in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.momentapharma.com
  • Investor Relations URL: http://ir.momentapharma.com/index.cfm
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: May. 01, 2020
  • Last Earnings Release: Feb. 26, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including M281, M254, and M230, are in development to treat rare autoimmune diseases.

Top Fund Holders

Symbol Name Weighting
PSCH Invesco S&P SmallCap Health Care ETF 4.23%
ETCHX Eventide Healthcare & Life Sciences C 1.89%
HGHVX Hartford Healthcare R6 1.29%
SPSM SPDR® Portfolio S&P 600 Sm Cap ETF 0.62%
SLY SPDR® S&P 600 Small Cap ETF 0.62%
IJR iShares Core S&P Small-Cap ETF 0.59%
VTSIX Vanguard Tax-Managed Small Cap I 0.48%
VSMSX Vanguard S&P Small-Cap 600 Index I 0.47%
VIOO Vanguard S&P Small-Cap 600 ETF 0.47%
DISIX BNY Mellon Small Cap Stock Index I 0.44%
CSPYX Columbia Small Cap Index Inst3 0.44%
FYX First Trust Small Cap Core AlphaDEX® ETF 0.42%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.